Page 82 - Read Online

Fonseka et al. J Cancer Metastasis Treat 2020;6:7 I http://dx.doi.org/10.20517/2394-4722.2019.024 Page 11 of 11

41. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
42. Hoffmann H. violin. m-Simple violin plot using matlab default kernel density estimation. Katzenburgweg, Germany: INRES (University
of Bonn) 2015.
43. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in
deciphering survival and drug responses of cancer patients. EMBO Mol Med 2014;6:1279-93.
44. Liang Z, Lu L, Mao J, Li X, Qian H, et al. Curcumin reversed chronic tobacco smoke exposure induced urocystic EMT and acquisition of
cancer stem cells properties via Wnt/beta-catenin. Cell Death Dis 2017;8:e3066.
45. Li F, Sun Y, Jia J, Yang C, Tang X, et al. Silibinin attenuates TGFbeta1induced migration and invasion via EMT suppression and is
associated with COX2 downregulation in bladder transitional cell carcinoma. Oncol Rep 2018;40:3543-50.
46. Cao L, Xiao X, Lei J, Duan W, Ma Q, et al. Curcumin inhibits hypoxia-induced epithelialmesenchymal transition in pancreatic cancer
cells via suppression of the hedgehog signaling pathway. Oncol Rep 2016;35:3728-34.
47. Kim JS, Han NK, Kim SH, Lee HJ. Silibinin attenuates radiation-induced intestinal fibrosis and reverses epithelial-to-mesenchymal
transition. Oncotarget 2017;8:69386-97.
48. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res 2004;10:4125-33.
49. Veas-Perez de Tudela M, Delgado-Esteban M, Cuende J, Bolanos JP, Almeida A. Human neuroblastoma cells with MYCN amplification
are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. J Neurochem 2010;113:819-25.
50. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203.
51. Smith V, Foster J. High-risk neuroblastoma treatment review. Children (Basel) 2018;5.
52. Kaczowka P, Wieczorek A, Czogala M, Ksiazek T, Szewczyk K, et al. The role of N-Myc gene amplification in neuroblastoma childhood
tumour - single-centre experience. Contemp Oncol (Pozn) 2018;22:223-8.
53. Picone P, Nuzzo D, Caruana L, Messina E, Scafidi V, et al. Curcumin induces apoptosis in human neuroblastoma cells via inhibition of
AKT and Foxo3a nuclear translocation. Free Radic Res 2014;48:1397-408.
54. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative,
cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40-59.
55. Deep G, Agarwal R. Anti-metastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer
Metastasis Rev 2010;29:447-63.
56. Wang Q, Qu C, Xie F, Chen L, Liu L, et al. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer
cells by inhibiting cancer-associated fibroblasts. Am J Cancer Res 2017;7:125-33.
57. Ramasamy TS, Ayob AZ, Myint HH, Thiagarajah S, Amini F. Targeting colorectal cancer stem cells using curcumin and curcumin
analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell Int 2015;15:96.
58. Kumar S, Raina K, Agarwal C, Agarwal R. Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by
modulating interleukin 4/6-mediated survival signals. Oncotarget 2014;5:4972-89.
59. Zang S, Liu T, Shi J, Qiao L. Curcumin: a promising agent targeting cancer stem cells. Anticancer Agents Med Chem 2014;14:787-92.
60. Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, et al. Factors associated with recurrence and survival length following relapse in
patients with neuroblastoma. Br J Cancer 2016;115:1048-57.
61. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, et al. Clinical and biologic features predictive of survival after relapse of
neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 2011;29:3286-92.
62. James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of
colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett 2015;364:135-41.
63. Irving GR, Iwuji CO, Morgan B, Berry DP, Steward WP, et al. Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX
chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. Trials 2015;16:110.
64. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al. Phase II trial of curcumin in patients with advanced
pancreatic cancer. Clin Cancer Res 2008;14:4491-9.
65. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic
patients with chronic hepatitis C. J Clin Pharmacol 2010;50:434-49.
66. Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the
treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 2010;116:506-13.
67. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate
cancer patients. Invest New Drugs 2007;25:139-46.